China Kanghui Holdings, a leading domestic developer, manufacturer and marketer of orthopedic implants in China, has announced that its initial public offering(IPO) of 6,675,000 American Depositary Shares (“ADSs”), representing 40,050,000 ordinary shares, was priced at $10.25 per ADS. The company is offering 5,340,000 ADSs, and the selling shareholders are offering 1,335,000 ADSs. The ADSs are expected to begin trading on the New York Stock Exchange   under the symbol “KH.”

The company has granted the underwriters a 30-day option to purchase up to 1,001,250 additional ADSs.

The company intends to use the net proceeds for the development of its product pipeline, expansion of its manufacturing capacities, enhancement of its sales and marketing capabilities as well as general corporate purposes.

Morgan Stanley and Piper Jaffray are acting as the joint book running managers of the offering. Cowen & Co and Canaccord Genuity are acting as co-managers.

Kanghui’s registration statement relating to these securities was declared effective on August 10, 2010 by the U.S. Securities and Exchange Commission.